{"product_id":"landogrozumab-ly2495655-10mg","title":"Landogrozumab (LY2495655) 10mg","description":"\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eDue to the nature of this product being a monoclonal antibody and thus must be manufactured and stored under stringent quality standards, order fulfillment requires additional processing time. Please allow 2–3 weeks for production, plus shipping time, to ensure we deliver a product that meets our quality and purity specifications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"549\" data-start=\"129\"\u003e\u003cstrong data-end=\"158\" data-start=\"129\"\u003eLandogrozumab (LY2495655)\u003c\/strong\u003e is a \u003cstrong data-end=\"197\" data-start=\"164\"\u003ehumanized monoclonal antibody\u003c\/strong\u003e that \u003cstrong data-end=\"236\" data-start=\"203\"\u003eneutralizes myostatin (GDF-8)\u003c\/strong\u003e, a TGF-β–superfamily ligand that acts as a \u003cstrong data-end=\"337\" data-start=\"280\"\u003edominant negative regulator of skeletal-muscle growth\u003c\/strong\u003e. The intent of myostatin blockade is to \u003cstrong data-end=\"421\" data-start=\"378\"\u003eincrease (or preserve) lean muscle mass\u003c\/strong\u003e and—if muscle quality and neuromuscular capacity allow—\u003cstrong data-end=\"510\" data-start=\"477\"\u003eimprove strength and function\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"670\" data-start=\"551\"\u003e\u003cstrong data-end=\"573\" data-start=\"551\"\u003eRegulatory status:\u003c\/strong\u003e investigational; \u003cstrong data-end=\"614\" data-start=\"591\"\u003eno FDA\/EMA approval\u003c\/strong\u003e for clinical use. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"675\" data-start=\"672\"\u003e\n\u003ch2 data-end=\"759\" data-start=\"677\"\u003e2) Target biology: why myostatin inhibition is compelling \u003c\/h2\u003e\n\u003cp data-end=\"1216\" data-start=\"760\"\u003eMyostatin signals primarily through \u003cstrong data-end=\"825\" data-start=\"796\"\u003eActRIIB\/ActRIIA → SMAD2\/3\u003c\/strong\u003e pathways to suppress anabolic programs and promote a catabolic tone in skeletal muscle. Inhibiting myostatin reliably increases muscle mass in many preclinical models; however, a key translational hurdle across the field is that \u003cstrong data-end=\"1139\" data-start=\"1055\"\u003emass gains do not consistently translate into meaningful functional improvements\u003c\/strong\u003e, especially in complex disease states. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"1221\" data-start=\"1218\"\u003e\n\u003ch2 data-end=\"1258\" data-start=\"1223\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"1314\" data-start=\"1260\"\u003e3.1 Ligand neutralization (primary pharmacology)\u003c\/h3\u003e\n\u003cul data-end=\"1619\" data-start=\"1315\"\u003e\n\u003cli data-end=\"1479\" data-start=\"1315\"\u003e\n\u003cp data-end=\"1479\" data-start=\"1317\"\u003e\u003cstrong data-end=\"1350\" data-start=\"1317\"\u003eLandogrozumab binds myostatin\u003c\/strong\u003e in the extracellular compartment, preventing interaction with activin type II receptors. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1619\" data-start=\"1480\"\u003e\n\u003cp data-end=\"1619\" data-start=\"1482\"\u003eDownstream consequence: \u003cstrong data-end=\"1535\" data-start=\"1506\"\u003ereduced SMAD2\/3 signaling\u003c\/strong\u003e, shifting muscle toward a more permissive anabolic environment (context-dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"1668\" data-start=\"1621\"\u003e3.2 Systems-level consequences (expected)\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2129\" data-start=\"1669\"\u003e\n\u003cthead data-end=\"1708\" data-start=\"1669\"\u003e\n\u003ctr data-end=\"1708\" data-start=\"1669\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"1678\" data-start=\"1669\"\u003eDomain\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"1699\" data-start=\"1678\"\u003eExpected direction\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"1708\" data-start=\"1699\"\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2129\" data-start=\"1724\"\u003e\n\u003ctr data-end=\"1820\" data-start=\"1724\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1741\" data-start=\"1724\"\u003eLean body mass\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1745\" data-start=\"1741\"\u003e↑\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1820\" data-start=\"1745\"\u003eMost consistent signal in trials. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1979\" data-start=\"1821\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1852\" data-start=\"1821\"\u003ePower\/functional performance\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1863\" data-start=\"1852\"\u003evariable\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1979\" data-start=\"1863\"\u003eEndpoint sensitivity + rehab\/training + baseline frailty determine signal. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2129\" data-start=\"1980\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2008\" data-start=\"1980\"\u003eCachexia-related outcomes\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2020\" data-start=\"2008\"\u003euncertain\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2129\" data-start=\"2020\"\u003eDisease biology and survival confounding complicate interpretation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2134\" data-start=\"2131\"\u003e\n\u003ch2 data-end=\"2203\" data-start=\"2136\"\u003e4) Pharmacokinetics \u0026amp; administration (practical trial framing)\u003c\/h2\u003e\n\u003cp data-end=\"2543\" data-start=\"2204\"\u003eAs an IgG monoclonal antibody, landogrozumab is expected to exhibit \u003cstrong data-end=\"2290\" data-start=\"2272\"\u003etypical mAb PK\u003c\/strong\u003e (limited distribution beyond vascular\/interstitial space; FcRn recycling; proteolytic clearance). In the most visible Phase 2 programs, it was administered \u003cstrong data-end=\"2465\" data-start=\"2447\"\u003esubcutaneously\u003c\/strong\u003e in repeated doses over weeks to months. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"2548\" data-start=\"2545\"\u003e\n\u003ch2 data-end=\"2618\" data-start=\"2550\"\u003e5) Clinical evidence: where it showed signal and where it did not\u003c\/h2\u003e\n\u003ch3 data-end=\"2677\" data-start=\"2620\"\u003e5.1 Older “weak fallers” (proof-of-concept Phase 2)\u003c\/h3\u003e\n\u003cp data-end=\"2943\" data-start=\"2678\"\u003eA randomized Phase 2 trial in \u003cstrong data-end=\"2730\" data-start=\"2708\"\u003eolder weak fallers\u003c\/strong\u003e reported that landogrozumab \u003cstrong data-end=\"2782\" data-start=\"2759\"\u003eincreased lean mass\u003c\/strong\u003e and “might improve” some measures of \u003cstrong data-end=\"2845\" data-start=\"2820\"\u003emuscle power\/function\u003c\/strong\u003e, supporting biological activity in a frail aging phenotype. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"3181\" data-start=\"2945\"\u003e\u003cstrong data-end=\"2972\" data-start=\"2945\"\u003eKey interpretive point:\u003c\/strong\u003e functional outcomes were not uniformly strong across all measures, which fits the broader myostatin-inhibitor pattern: \u003cstrong data-end=\"3142\" data-start=\"3092\"\u003elean mass improves more reliably than function\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"3186\" data-start=\"3183\"\u003e\n\u003ch3 data-end=\"3269\" data-start=\"3188\"\u003e5.2 Elective total hip arthroplasty (perioperative sarcopenia\/stress model)\u003c\/h3\u003e\n\u003cp data-end=\"3728\" data-start=\"3270\"\u003eIn a Phase 2 randomized study in patients undergoing \u003cstrong data-end=\"3358\" data-start=\"3323\"\u003eelective total hip arthroplasty\u003c\/strong\u003e, landogrozumab produced \u003cstrong data-end=\"3424\" data-start=\"3383\"\u003edose-dependent increases in lean mass\u003c\/strong\u003e, but \u003cstrong data-end=\"3469\" data-start=\"3430\"\u003edid not show meaningful differences\u003c\/strong\u003e for many exploratory functional endpoints versus placebo. Importantly, \u003cstrong data-end=\"3569\" data-start=\"3541\"\u003einjection-site reactions\u003c\/strong\u003e were more common with landogrozumab; otherwise no major safety signal was highlighted in the abstract-level reporting. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"3973\" data-start=\"3730\"\u003e\u003cstrong data-end=\"3769\" data-start=\"3730\"\u003eWhat this suggests mechanistically:\u003c\/strong\u003e perioperative catabolism is a strong stress test for anabolic agents, but \u003cstrong data-end=\"3910\" data-start=\"3844\"\u003erehab intensity, pain-limited performance, and endpoint timing\u003c\/strong\u003e can blunt measurable function gains even when lean mass rises.\u003c\/p\u003e\n\u003chr data-end=\"3978\" data-start=\"3975\"\u003e\n\u003ch3 data-end=\"4050\" data-start=\"3980\"\u003e5.3 Pancreatic cancer + chemotherapy (cachexia-targeted Phase 2)\u003c\/h3\u003e\n\u003cp data-end=\"4394\" data-start=\"4051\"\u003eA randomized Phase 2 trial evaluated landogrozumab (100 mg or 300 mg) \u003cstrong data-end=\"4163\" data-start=\"4121\"\u003eadded to standard-of-care chemotherapy\u003c\/strong\u003e in \u003cstrong data-end=\"4200\" data-start=\"4167\"\u003estage II–IV pancreatic cancer\u003c\/strong\u003e, stratified by cachexia status. The published report concluded that landogrozumab \u003cstrong data-end=\"4318\" data-start=\"4283\"\u003edid not confer clinical benefit\u003c\/strong\u003e in the intention-to-treat analysis. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"4640\" data-start=\"4396\"\u003e\u003cstrong data-end=\"4443\" data-start=\"4396\"\u003eWhy cachexia trials are uniquely difficult:\u003c\/strong\u003e survival, treatment tolerance, inflammation, tumor burden, and heterogeneity in nutritional and activity status can overwhelm a single-pathway muscle intervention—even if target engagement occurs.\u003c\/p\u003e\n\u003chr data-end=\"4645\" data-start=\"4642\"\u003e\n\u003ch2 data-end=\"4701\" data-start=\"4647\"\u003e6) Safety and tolerability (what’s most defensible)\u003c\/h2\u003e\n\u003cp data-end=\"4795\" data-start=\"4702\"\u003eAcross the better-indexed Phase 2 reporting, the most consistently noted adverse effect is:\u003c\/p\u003e\n\u003cul data-end=\"4889\" data-start=\"4796\"\u003e\n\u003cli data-end=\"4889\" data-start=\"4796\"\u003e\n\u003cp data-end=\"4889\" data-start=\"4798\"\u003e\u003cstrong data-end=\"4826\" data-start=\"4798\"\u003eInjection-site reactions\u003c\/strong\u003e (higher than placebo). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"4967\" data-start=\"4891\"\u003eMechanism-informed considerations for any myostatin inhibitor (class-level):\u003c\/p\u003e\n\u003cul data-end=\"5461\" data-start=\"4968\"\u003e\n\u003cli data-end=\"5100\" data-start=\"4968\"\u003e\n\u003cp data-end=\"5100\" data-start=\"4970\"\u003e\u003cstrong data-end=\"5001\" data-start=\"4970\"\u003e“Quantity vs quality” risk:\u003c\/strong\u003e muscle hypertrophy without proportional neuromuscular adaptation may limit functional improvement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5267\" data-start=\"5101\"\u003e\n\u003cp data-end=\"5267\" data-start=\"5103\"\u003e\u003cstrong data-end=\"5144\" data-start=\"5103\"\u003eTendon\/entheseal adaptation mismatch:\u003c\/strong\u003e theoretically relevant if activity increases rapidly (general physiology principle; not specific proof for landogrozumab).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5461\" data-start=\"5268\"\u003e\n\u003cp data-end=\"5461\" data-start=\"5270\"\u003e\u003cstrong data-end=\"5299\" data-start=\"5270\"\u003eDisease-context barriers:\u003c\/strong\u003e fibrosis, fatty infiltration, denervation, and systemic inflammation can reduce the functional translation of mass gains. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5466\" data-start=\"5463\"\u003e\n\u003ch2 data-end=\"5522\" data-start=\"5468\"\u003e7) Why results were mixed: a scientific synthesis\u003c\/h2\u003e\n\u003cp data-end=\"5583\" data-start=\"5523\"\u003eLandogrozumab largely supports three field-wide conclusions:\u003c\/p\u003e\n\u003col data-end=\"6288\" data-start=\"5585\"\u003e\n\u003cli data-end=\"5783\" data-start=\"5585\"\u003e\n\u003cp data-end=\"5783\" data-start=\"5588\"\u003e\u003cstrong data-end=\"5623\" data-start=\"5588\"\u003eLean mass is the easy endpoint.\u003c\/strong\u003e\u003cbr data-end=\"5626\" data-start=\"5623\"\u003eTrials in older adults and surgical stress settings show consistent directionality toward \u003cstrong data-end=\"5742\" data-start=\"5719\"\u003eincreased lean mass\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5993\" data-start=\"5785\"\u003e\n\u003cp data-end=\"5993\" data-start=\"5788\"\u003e\u003cstrong data-end=\"5822\" data-start=\"5788\"\u003eFunction is the hard endpoint.\u003c\/strong\u003e\u003cbr data-end=\"5825\" data-start=\"5822\"\u003eFunctional changes are smaller, noisier, and highly dependent on baseline physiology, rehab\/training, and endpoint selection. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6288\" data-start=\"5995\"\u003e\n\u003cp data-end=\"6288\" data-start=\"5998\"\u003e\u003cstrong data-end=\"6046\" data-start=\"5998\"\u003eCachexia needs more than myostatin blockade.\u003c\/strong\u003e\u003cbr data-end=\"6049\" data-start=\"6046\"\u003eIn pancreatic cancer, adding landogrozumab did not deliver meaningful clinical benefit, underscoring the multi-factor biology of cancer cachexia and the importance of survival-aware trial designs. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-end=\"6293\" data-start=\"6290\"\u003e\n\u003ch2 data-end=\"6351\" data-start=\"6295\"\u003e8) Position in the broader landscape (2020s re-frame)\u003c\/h2\u003e\n\u003cp data-end=\"6875\" data-start=\"6352\"\u003eThe field’s strategic re-frame—especially in the GLP-1 era—is to deploy muscle-directed biologics to \u003cstrong data-end=\"6494\" data-start=\"6453\"\u003epreserve lean mass during weight loss\u003c\/strong\u003e or during other catabolic states, rather than expecting myostatin inhibition alone to “fix” function in advanced disease. Reviews and perspectives discussing landogrozumab place it among the myostatin mAbs that demonstrated \u003cstrong data-end=\"6772\" data-start=\"6719\"\u003emass gains with inconsistent function translation\u003c\/strong\u003e, helping motivate newer modalities and combination strategies. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"6880\" data-start=\"6877\"\u003e\n\u003ch2 data-end=\"6948\" data-start=\"6882\"\u003e9) Future directions (what would have to be proven for success)\u003c\/h2\u003e\n\u003cp data-end=\"7037\" data-start=\"6949\"\u003eIf a landogrozumab-like program were pursued today, the highest-value upgrades would be:\u003c\/p\u003e\n\u003cul data-end=\"7662\" data-start=\"7039\"\u003e\n\u003cli data-end=\"7180\" data-start=\"7039\"\u003e\n\u003cp data-end=\"7180\" data-start=\"7041\"\u003e\u003cstrong data-end=\"7073\" data-start=\"7041\"\u003eFunction-first trial design:\u003c\/strong\u003e power, stair climb, sit-to-stand, VO₂peak, falls, ADLs—paired with standardized resistance training\/rehab.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7324\" data-start=\"7181\"\u003e\n\u003cp data-end=\"7324\" data-start=\"7183\"\u003e\u003cstrong data-end=\"7212\" data-start=\"7183\"\u003eBody composition quality:\u003c\/strong\u003e MRI muscle volume, intramuscular fat, strength per unit cross-sectional area (muscle “quality”), not DXA alone.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7544\" data-start=\"7325\"\u003e\n\u003cp data-end=\"7544\" data-start=\"7327\"\u003e\u003cstrong data-end=\"7359\" data-start=\"7327\"\u003eTarget population selection:\u003c\/strong\u003e older adults with low muscle reserve, GLP-1 users with rapid weight loss, or post-hospitalization recovery cohorts—settings where lean mass preservation has clearer clinical relevance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7662\" data-start=\"7545\"\u003e\n\u003cp data-end=\"7662\" data-start=\"7547\"\u003e\u003cstrong data-end=\"7574\" data-start=\"7547\"\u003eMechanistic biomarkers:\u003c\/strong\u003e SMAD2\/3 signatures, muscle protein synthesis markers, and digital functional endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684838371666,"sku":null,"price":7000.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Landogrozumab_10mg.png?v=1770834787","url":"https:\/\/sciencepeptideslab.com\/products\/landogrozumab-ly2495655-10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}